Post-market Examination of Biosimilars & Novel Biologics: The BBCIC 2016 Surveillance Plan
Webinar Recorded on March 23, 2016
As biosimilars come to market, physicians and patients will have questions about the safety and effectiveness of these products, similar to what was experienced with the introduction of generics more than a generation ago.
The BBCIC harnesses cutting-edge distributed research network technology and surveillance methods to provide the reassurance that patients and physicians want.
In this webinar, we’ll introduce our BBCIC founders and discuss our 2016 BBCIC Research Plan.
Where Can I Find Out More?
Learn more about how your AMCP membership puts you at the forefront of the latest real-world research methods at www.bbcic.org.
Bernadette Eichelberger, PharmD
Program Director, Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)